This page shows the latest oncolytic viruses news and features for those working in and with pharma, biotech and healthcare.
These trials are designed to investigate Libtayo across a range of settings, monotherapy and in combination with chemotherapy and novel agents including vaccines, oncolytic viruses and bispecific antibodies and others.
AstraZeneca has similar plans to combined Transgene’s oncolytic viruses withits in-house pipeline ofImmuno-oncology (IO) treatments. ... AstraZeneca's Jean-Charles Soria. Jean-Charles Soria, AstraZeneca’s senior vice president, Oncology R&D, said:
Paragon, which is backed by private-equity firms Camden Partners and NewSpring Capital, helps its clients develop and produce gene therapies, next-generation vaccines, and other complex biopharmaceuticals such as oncolytic ... viruses and CAR-T cell
The company currently has clinical-phase projects ranging across checkpoint inhibitors, oncolytic viruses, cancer vaccines and T-cell engagers, with around half of its early-to-mid-stage pipeline emerging from ... 2006. Other oncolytic virus candidates
Oncolytic viruses are engineered to selectively replicate within and destroy cancer cells while simultaneously augmenting anti-tumour immunity, and are generally injected directly into tumour sites. ... There’s a lot of activity going on in R&D however,
that the promise of oncolytic viruses will come to fruition when they are used in combination with other cancer immunotherapies. ... The biotech’s website indicates that its oncolytic viruses lend themselves to co-administration with immune checkpoint
More from news
Approximately 2 fully matching, plus 10 partially matching documents found.
cell-based therapies and oncolytic viruses that attack malignant cells directly, and cancer vaccines that try to kickstart an intrinsic immune reaction to the tumour. ... Oncolytic viruses. An oncolytic virus is a virus that preferentially infects and
From a payload perspective, these include new technologies such as siRNA, Sleeping Beauty transposases, CRISPR-Cas9 gene editing, ARCUS gene editing, nucleic acid vaccines, oncolytic viruses and chemically modified mRNA. ... In contrast, viruses still
995+. PsiOxus Therapeutics (UK). BMS (US). Licence. NG-348: preclinical “armed” oncolytic virus targeting tumour cells. ... technology in the development of immunomodulatory oncolytic viruses.
His fundamental idea is to create synthetic viruses that can invade cancer cells, destroy them, and then multiply into more viruses to kill the remaining cancerous cells. ... This forms part of a new research area known as oncolytic virology that uses
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Oncolytic viruses and cancer vaccines have the potential to benefits a wide range of patients living with cancer, and the company’s proprietary viral platform technology is at the forefront of ... we advance clinical development of our next-generation
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
In addition, developments in oncolytic viruses mean the options for patients with certain solid tumours are ever-expanding.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...